Remedee Labs’ Solution becomes the first CE marked medical device (class IIa) approved for the treatment of fibromyalgia in Europe Read the press release.
Contact us

OUR MISSION

Improving quality of life for millions of people with chronic pain

Founded in 2016 in Grenoble, France, by specialists in the areas micro and nano medical technologies and biomedical research, the company boasts a multidisciplinary, international team.

Remedee Labs combines medical research, cutting-edge technology and digital solutions to help millions of people with chronic pain regain control of their lives.

Key events & milestones

2024

  • Remedee Labs’ Solution becomes the first CE marked medical device (class IIa) approved for the treatment of fibromyalgia in Europe
    The Remedee Labs solution is the first medical device clinically validated and certified in Europe to provide symptom relief for fibromyalgia, a disorder for which no specific treatment had previously been identified.

2023

  • Remedee Labs announces positive results from its clinical trial on fibromyalgia
    The study showed a clear improvement in patients’ quality of life, as well as a significant decrease in pain, generalized and physical fatigue, anxiety, and depression, and an improvement in sleep quality.
  • Remedee Labs announces positive results from its clinical trial on osteoarthritis.
    The initial results showed a significant decrease in pain and an improvement in sleep quality and overall quality of life among patients who used the device.
  • UPSA and the startup Remedee Labs announce a partnership
    UPSA’s pharmaceutical sales representatives will meet with healthcare professionals—primary care physicians and rheumatologists—to present Remedee Well solution.

2022

    • FDA Grants Breakthrough Device Designation to Remedee Labs for the management of Fibromyalgia
    • Serie A : Remedee Labs raised €12.2 million from investors including Generali France.

 

2021

  • Remedee Labs joins Future4care, the digital health startup accelerator.
  • Fibrepik protocol submission for Fibromyalgia pain management
  • Inclusion of the first patients in the Epikarthrose protocol for arthritis pain management

2020

  •   Remedee Labs joins 2 major international healthcare networks: Medtech Innovator & JLABS by Johnson & Johnson Innovation

2019

  • Pre-Series A financing completed
  • ISO 13485 certification obtained

2018

  • Remedee Labs’ first complete personal endorphin stimulation device delivered.
  • Clinical validation of millimeter wave treatment innocuity.

2017

MEET module patented by Remedee Labs
Remedee Labs develops its patented technology of a millimeter wave emitting module for medical usage.

2016

Remedee Labs is created

A team of experts

Remedee Labs is today a multidisciplinary, international team of 40 people. Our areas of expertise cover medical research, microelectronics, software development, artificial intelligence and more. At the heart of our ambitious project are people and human values.

Jacques HUSSER

Co-founder & Exec Chairman

Co-founder and Exec Chairman Jacques Husser served most recently as COO of French IoT company Sigfox, recognized as one of France’s highly successful startups and now a global leader in IoT wireless networks and services. Having raised over €300m and establishing itself in over 60 countries, Sigfox is now a key international technology company. An expert in business strategy, vision and organization, Husser has also held leadership positions in a telehealth company, as well as heading one of the Building Automation divisions of the Hager group.

David CROUZIER

Co-founder & CEO

Co-founder and CEO David Crouzier has 15 years’ experience in the field of biomedical research. A recognized authority, Crouzier was previously head of a French Department of Defense research laboratory. His research into non-ionizing radiation and electromagnetic biological effects has contributed to publications on health and safety risks of emerging technologies for the National Agency for Food Safety, the Environment and Work (ANSES) in France.

Michael FOERSTER

Co-founder & CTO

Co-founder and CTO Michael Foerster is an expert in implanted medical devices and health technology innovation, Foerster has also worked on the design of active implantable brain-machine interfaces for quadriplegic patients at the CEA-Clinatec medical technology research center in Grenoble. He is also a multiple high-tech entrepreneur, having also co-founded mountain sport technology company NIVOLOG.

Gilles LITMAN

Chief Business Officer

Graduate of ESSEC Paris, Gilles has over 20 years’ experience in the pharmaceutical industry, especially strategy, international development and business management. Before joining Remedee Labs, Gilles was the VP of Digital Health at Sanofi, where he worked on digital platforms focused on diabetes and cardiovascular diseases.

Scientific advisory board

Comprised of leading experts in neuromodulation, pain management and electromagnetic waves the Scientific Advisory Board provides strategic and scientific counsel to advance the development of Remedee Labs’ solution.

Thierry BOSC

President of Remedee Labs’ scientific advisory board & Director of the CEA-Clinatec endowment fund

Dr. Caroline MAINDET

Grenoble teaching hospital / Doctor at the Center for Pain Management

Pr. Pierre ALBALADEJO

Grenoble teaching hospital, Department of Anesthesia & Intensive care

Dr. Yves LE DREAN

Rennes 1 University – IRSET – Inserm UMR 1085, Expert in the biological effects of electromagnetic waves

Pr. Alain SERRIE (MD-PhD)

Head of the department of Pain Medicine & Palliative Care, President & founder of the Douleur sans frontières association

Last News